'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers
Executive Summary
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
You may also be interested in...
Pretomanid Price Cut By 34% But Access Complexities Remain
Viatris, MedAccess and TB Alliance deal to lower the price of pretomanid, a key drug used as part of a shorter all-oral drug regime for multidrug-resistant TB, but country-level prioritization and uptake of the treatment option will be pivotal to widen access sharply.
TB Alliance CEO On Derailed Treatment In Ukraine, Pediatric Pretomanid Plans
TB Alliance CEO Mel Spigelman discusses the huge disruptions in TB treatment in war-ravaged Ukraine, and need for funding, political will and resources along the lines of that galvanized for COVID-19, or "even a fraction" of that, to control the deadly infectious disease. He also touched on the accelerated availability of the BPaL regimen and a partnered program for an anti-TB natural product.
TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans
TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.